-
Aug 23, 2024 | 
pharmacytimes.com | Sophia Z. Humphreys
August 23, 2024By Sophia Humphreys, PharmD, MHA, BCBBS, discusses biosimilar utilization and inventory management. Video content above is prompted by the following:How has the introduction of biosimilars affected the biologic landscape at specialty pharmacies, including the disease states treated and trends in utilization?
-
Aug 23, 2024 | 
pharmacytimes.com | Sophia Z. Humphreys
Sophia Humphreys, PharmD, MHA, BCBBS, discusses the key differences between biologics and biosimilars. Video content above is prompted by the following:• What are key differences between biologics and biosimilars in terms of safety, efficacy, and FDA approval, and what sets biosimilars apart from one another?
-
Jul 23, 2024 | 
ajmc.com | Sophia Z. Humphreys |Chad Cannon |Eric Tichy |Susan Peppers
OpinionVideoJuly 23, 2024Author(s):,The expert panel discusses the greater potential for private label biosimilars. Video content above is prompted by the following questions:Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?
-
May 13, 2024 | 
pharmacytimes.com | Sophia Z. Humphreys
In December 2023, the FDA approved the first 2 curative cell-based gene therapy agents for sickle cell disease in patients 12 years and older: exagamglogene autotemcel (exa-cel; Casgevy; Vertex Pharmaceuticals Incorporated) and lovotibeglogene autotemcel (lovo-cel; Lyfgenia; bluebird bio, Inc).
-
May 10, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 10, 2024Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The conversation delves into various educational resources utilized both by healthcare providers and patients regarding ddalimumab biosimilars.
-
May 10, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 10, 2024Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
-
May 10, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 10, 2024Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The dialogue revolves around patient education regarding biosimilar medications, focusing on common questions and concerns raised by patients and healthcare providers.
-
May 3, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 3, 2024Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
-
May 3, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 3, 2024Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The discussion centers on how healthcare professionals can promote the use of adalimumab biosimilars and enhance patient care.
-
Apr 29, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
April 29, 2024Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The discussion revolves around experiences initiating patients on biosimilars.
